Safety and activity of <scp>anti‐CD14</scp> antibody <scp>IC14</scp> (atibuclimab) in <scp>ALS</scp> : Experience with expanded access protocol-Reference-Cited by-同舟云学术

Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS : Experience with expanded access protocol

Published:2022-12-30 Issue:5 Volume:67 Page:354-362
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle and Nerve

Author:

Gelevski Dario¹^ORCID,Addy Grace¹,Rohrer Margot¹,Cohen Caroline¹,Roderick Aimee¹,Winter Allison¹,Carey Judith¹,Scalia Jennifer¹,Yerton Megan¹,Weber Harli¹,Doyle Michael¹,Parikh Neil¹,Kane Geli¹,Ellrodt Amy¹,Burke Katherine¹^ORCID,D'Agostino Derek¹,Sinani Ervin²,Yu Hong¹,Sherman Alexander¹,Agosti Jan²,Redlich Garry²,Charmley Patrick²,Crowe David²,Appleby Mark²,Ziegelaar Brian²,Hanus Katherine³,Li Zhenhua³,Babu Suma¹,Nicholson Katharine¹,Luppino Sarah¹,Berry James¹^ORCID,Baecher‐Allan Clare³,Paganoni Sabrina¹⁴^ORCID,Cudkowicz Merit¹^ORCID

Affiliation:

1. Department of Neurology Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School Boston Massachusetts United States

2. Implicit Bioscience, Ltd Brisbane Australia

3. Department of Neurology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts United States

4. Department of Physical Medicine and Rehabilitation Spaulding Rehabilitation Hospital, Harvard Medical School Boston Massachusetts United States

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27775

Reference36 articles.

1. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis

2. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial